Shopping Cart 0
Cart Subtotal
USD 0

Akebia Therapeutics Inc (AKBA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF-PH inhibitor, a regulator for the production of red blood cells, or RBCs, in the body, as well as other important metabolic functions for the treatment of anemia due to chronic kidney disease (CKD). The company's product pipeline includes AKB-5169, an oral treatment for inflammatory bowel disease. The company works in partnership with Otsuka Pharmaceutical Company Ltd, Mitsubishi Tanabe Pharma Corporation, and Vifor Pharma Management Ltd for the development and commercialization of its pipeline products. The company operates in the US and Ireland. Akebia Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Akebia Therapeutics Inc (AKBA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Akebia Therapeutics Raises USD 41 Million In Series C Financing 13

Akebia Therapeutics Secures Additional USD 4.1 Million In Series B Financing 15

Partnerships 16

Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 16

Merger 17

Akebia Therapeutics and Keryx Biopharma to Merge 17

Licensing Agreements 19

Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 19

Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 20

Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 22

Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 24

Equity Offering 25

Akebia Therapeutics Prices Public Offering of Shares for up to USD89 Million 25

Akebia Therapeutics Raises USD66.7 Million in Public Offering of Shares 26

Akebia Therapeutics Raises USD25.7 million Public Offering of Shares 28

Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 29

Akebia Therapeutics Files Registration Statement for Public Offering of Shares for up to USD100 Million 30

Akebia Therapeutics Raises USD75 Million in Public Offering of Shares 31

Akebia Therapeutics Raises USD69 Million in Public Offering of Shares 33

Akebia Therapeutics Completes IPO For USD 115 Million 34

Akebia Therapeutics Inc-Key Competitors 36

Akebia Therapeutics Inc-Key Employees 37

Akebia Therapeutics Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Aug 08, 2018: Akebia Therapeutics announces second quarter 2018 financial results 39

May 09, 2018: Akebia Therapeutics Announces First Quarter 2018 Financial Results 41

Mar 12, 2018: Akebia Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results 42

Nov 08, 2017: Akebia Therapeutics Announces Third Quarter 2017 Financial Results 44

Aug 08, 2017: Akebia Announces Second Quarter 2017 Financial Results 45

May 09, 2017: Akebia Announces First Quarter 2017 Financial Results 46

Mar 06, 2017: Akebia Announces Fourth Quarter and Full-Year 2016 Financial Results 47

Corporate Communications 49

Aug 28, 2018: Akebia Therapeutics names Cynthia Smith to its board of directors 49

May 25, 2017: Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer 50

Clinical Trials 51

Feb 12, 2018: Akebia Therapeutics Provides Update on Vadadustat Development Program 51

Jan 04, 2018: Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease 53

Nov 01, 2017: Notice of the Start of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Renal Anemia 54

Sep 26, 2017: Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease 55

May 24, 2017: Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents 56

Mar 28, 2017: Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akebia Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Akebia Therapeutics Raises USD 41 Million In Series C Financing 13

Akebia Therapeutics Secures Additional USD 4.1 Million In Series B Financing 15

Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 16

Akebia Therapeutics and Keryx Biopharma to Merge 17

Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 19

Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 20

Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 22

Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 24

Akebia Therapeutics Prices Public Offering of Shares for up to USD89 Million 25

Akebia Therapeutics Raises USD66.7 Million in Public Offering of Shares 26

Akebia Therapeutics Raises USD25.7 million Public Offering of Shares 28

Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 29

Akebia Therapeutics Files Registration Statement for Public Offering of Shares for up to USD100 Million 30

Akebia Therapeutics Raises USD75 Million in Public Offering of Shares 31

Akebia Therapeutics Raises USD69 Million in Public Offering of Shares 33

Akebia Therapeutics Completes IPO For USD 115 Million 34

Akebia Therapeutics Inc, Key Competitors 36

Akebia Therapeutics Inc, Key Employees 37

Akebia Therapeutics Inc, Subsidiaries 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Akebia Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF-PH inhibitor, a regulator for the production of red blood cells, or RBCs, in the body, as well as other important metabolic functions for the treatment of anemia due to chronic kidney disease (CKD). The company's product pipeline includes AKB-5169, an oral treatment for inflammatory bowel disease. The company works in partnership with Otsuka Pharmaceutical Company Ltd, Mitsubishi Tanabe Pharma Corporation, and Vifor Pharma Management Ltd for the development and commercialization of its pipeline products. The company operates in the US and Ireland. Akebia Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Akebia Therapeutics Inc (AKBA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Akebia Therapeutics Raises USD 41 Million In Series C Financing 13

Akebia Therapeutics Secures Additional USD 4.1 Million In Series B Financing 15

Partnerships 16

Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 16

Merger 17

Akebia Therapeutics and Keryx Biopharma to Merge 17

Licensing Agreements 19

Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 19

Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 20

Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 22

Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 24

Equity Offering 25

Akebia Therapeutics Prices Public Offering of Shares for up to USD89 Million 25

Akebia Therapeutics Raises USD66.7 Million in Public Offering of Shares 26

Akebia Therapeutics Raises USD25.7 million Public Offering of Shares 28

Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 29

Akebia Therapeutics Files Registration Statement for Public Offering of Shares for up to USD100 Million 30

Akebia Therapeutics Raises USD75 Million in Public Offering of Shares 31

Akebia Therapeutics Raises USD69 Million in Public Offering of Shares 33

Akebia Therapeutics Completes IPO For USD 115 Million 34

Akebia Therapeutics Inc-Key Competitors 36

Akebia Therapeutics Inc-Key Employees 37

Akebia Therapeutics Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Aug 08, 2018: Akebia Therapeutics announces second quarter 2018 financial results 39

May 09, 2018: Akebia Therapeutics Announces First Quarter 2018 Financial Results 41

Mar 12, 2018: Akebia Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results 42

Nov 08, 2017: Akebia Therapeutics Announces Third Quarter 2017 Financial Results 44

Aug 08, 2017: Akebia Announces Second Quarter 2017 Financial Results 45

May 09, 2017: Akebia Announces First Quarter 2017 Financial Results 46

Mar 06, 2017: Akebia Announces Fourth Quarter and Full-Year 2016 Financial Results 47

Corporate Communications 49

Aug 28, 2018: Akebia Therapeutics names Cynthia Smith to its board of directors 49

May 25, 2017: Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer 50

Clinical Trials 51

Feb 12, 2018: Akebia Therapeutics Provides Update on Vadadustat Development Program 51

Jan 04, 2018: Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease 53

Nov 01, 2017: Notice of the Start of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Renal Anemia 54

Sep 26, 2017: Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease 55

May 24, 2017: Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents 56

Mar 28, 2017: Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akebia Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Akebia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Akebia Therapeutics Raises USD 41 Million In Series C Financing 13

Akebia Therapeutics Secures Additional USD 4.1 Million In Series B Financing 15

Akebia Therapeutics Enters into Agreement with Mitsubishi Tanabe Pharma 16

Akebia Therapeutics and Keryx Biopharma to Merge 17

Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 19

Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 20

Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 22

Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 24

Akebia Therapeutics Prices Public Offering of Shares for up to USD89 Million 25

Akebia Therapeutics Raises USD66.7 Million in Public Offering of Shares 26

Akebia Therapeutics Raises USD25.7 million Public Offering of Shares 28

Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 29

Akebia Therapeutics Files Registration Statement for Public Offering of Shares for up to USD100 Million 30

Akebia Therapeutics Raises USD75 Million in Public Offering of Shares 31

Akebia Therapeutics Raises USD69 Million in Public Offering of Shares 33

Akebia Therapeutics Completes IPO For USD 115 Million 34

Akebia Therapeutics Inc, Key Competitors 36

Akebia Therapeutics Inc, Key Employees 37

Akebia Therapeutics Inc, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Akebia Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.